This Analyst Is Bullish On Biohaven’s Approach in Neuro-Psych Space
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000's Phase 3 trial this year, reducing late-stage risks.
FDA Fast-Tracks Review Of Sarepta’s Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.
Why Is Gilead Sciences Stock Trading Lower Today?
Gilead Sciences' global enrollment pause in magrolimab solid tumor studies. FDA issues partial clinical hold. Explore the impact on ongoing trials.
Why Is Liver Disease-Focused Inventiva Stock Trading Lower Today?
Inventiva announces a voluntary pause in NATiV3 Phase 3 trial of lanifibranor for NASH due to a treatment-related SUSAR. Screening and randomization halted temporarily.
Novartis Announces The FDA Has Approved Xolair As First And Only Medicine For Children And Adults With One Or More Food Allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts
What’s Going On With Stress Hormone Modulator-Focused Corcept Therapeutics’ Stock Friday?
Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes.
Fusion Pharmaceuticals Enters Into Exclusive Worldwide License Agreement With Heidelberg University And Euratom For Actinium-Based PSMA Targeted Radiotherapy
FPI-2265 positioned to be the first approved PSMA targeted alpha therapyHAMILTON, ON and BOSTON, Feb. 16, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on
Autonomix Announces The Completion Of Its Site Initiation For Its Proof-Of-Concept Human Clinical Study Evaluating The Use Of Transvascular RF Ablation For The Treatment Of Pancreatic Cancer Pain
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancerTHE WOODLANDS, TX, Feb. 16, 2024 (GLOBE NEWSWIRE) --